Hear from Allison Moore, Founder/CEO of the Hereditary Neuropathy Foundation about the past, present and future or CMT research.
6,000+ Strong Across 72 Countries — 2025 GRIN is Changing the Game for CMT Research! We’re...
A New CMT Treatment Is One Step Closer Augustine Therapeutics Begins Phase I Trial of AGT‑100216...
CMT-SORD Clinical Trial Update Promising Results from the INSPIRE Study on Govorestat! We’re...
Mark your calendars for April 24–26, 2025, because the Nashville CMT Summit is bringing the...
On March 19th, at the MDA Clinical and Scientific Conference in Dallas, TX, Dr. Cornett will...
CMT Summit + Retreat 2025: Uniting Patients, Researchers, Regulators, and Industry Leaders to...
Early preclinical research indicates that ALE2 could effectively slow or halt the progression of these debilitating symptoms, offering new hope for patients with these rare forms of CMT.
CMT Simplified is here to make staying informed about Charcot-Marie-Tooth disease (CMT) easier...
NMD670, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA)
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-MarieTooth Disease Type 1...
0 Comments